DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

JBT-101

Phase Two

Phase Two

Therapeutic Approach

Anti-Inflammatory

JBT-101 (Resunab™) is an oral drug that is aimed at promoting the resolution of inflammation. It is thought to increase production of anti-inflammatory molecules while reducing production of molecules that increase inflammation. Reduction of inflammation helps prevent permanent tissue damage in the lungs.

Status

 A phase 2 trial is underway.

Sponsor

This program is sponsored by Corbus and partially funded by the Cystic Fibrosis Foundation Therapeutics (CFFT). It is being conducted within CFFT's Therapeutics Development Network.

Contact us about JBT-101 >